Clarity Pharmaceuticals Ltd (ASX:CU6)

Clarity Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Other Revenue	9.46	11.51	9.8	6.46	3.2
Revenue	9.46	11.51	9.8	6.46	3.2
Revenue Growth (YoY)	-17.76%	17.41%	51.74%	102.07%	14.62%
Gross Profit	9.46	11.51	9.8	6.46	3.2
Selling, General & Admin	11.68	9.94	4.71	4.61	3.83
Research & Development	66.88	45.78	31.46	18.9	9.68
Operating Expenses	78.56	55.72	36.16	23.51	13.51
Operating Income	-69.09	-44.21	-26.36	-17.05	-10.31
Interest & Investment Income	4.76	2.77	1.86	0.1	0.04
Currency Exchange Gain (Loss)	0.45	-0.59	-	-	-
EBT Excluding Unusual Items	-63.88	-42.03	-24.5	-16.95	-10.27
Other Unusual Items	-	-	-	-6.78	0.05
Pretax Income	-63.88	-42.03	-24.5	-23.74	-10.22
Income Tax Expense	0.42	0.3	0.1	0.02	-
Net Income	-64.3	-42.32	-24.6	-23.75	-10.22
Net Income to Common	-64.3	-42.32	-24.6	-23.75	-10.22
Shares Outstanding (Basic)	319	273	260	248	176
Shares Outstanding (Diluted)	319	273	260	248	176
Shares Change (YoY)	16.86%	5.22%	4.81%	40.37%	20.54%
EPS (Basic)	-0.20	-0.15	-0.09	-0.10	-0.06
EPS (Diluted)	-0.20	-0.15	-0.10	-0.10	-0.06
Free Cash Flow	-54.95	-43.74	-27.55	-13.53	-7.74
Free Cash Flow Per Share	-0.17	-0.16	-0.11	-0.06	-0.04
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-730.16%	-384.24%	-269.00%	-263.94%	-322.65%
Profit Margin	-679.45%	-367.82%	-251.03%	-367.78%	-319.77%
Free Cash Flow Margin	-580.71%	-380.14%	-281.07%	-209.43%	-242.06%
EBITDA	-68.91	-44.06	-26.26	-17	-10.3
EBITDA Margin	-	-	-267.97%	-263.22%	-
D&A For EBITDA	0.19	0.15	0.1	0.05	0.02
EBIT	-69.09	-44.21	-26.36	-17.05	-10.31
EBIT Margin	-	-	-269.00%	-263.94%	-
Revenue as Reported	14.68	14.28	11.66	6.55	3.29

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.